Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. The company is headquartered in Solana Beach, California and currently employs 3 full-time employees. The company went IPO on 2013-09-25. The company develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. The company has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
Follow-Up Questions
Qui est le CEO de Evoke Pharma Inc ?
Mr. Matthew D'Onofrio est le President de Evoke Pharma Inc, il a rejoint l'entreprise depuis 2007.
Quelle est la performance du prix de l'action EVOK ?
Le prix actuel de EVOK est de $5.11, il a increased de 0.59% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Evoke Pharma Inc ?
Evoke Pharma Inc appartient à l'industrie Pharmaceuticals et le secteur est Health Care
Quelle est la capitalisation boursière de Evoke Pharma Inc ?
La capitalisation boursière actuelle de Evoke Pharma Inc est de $7.9M
Est-ce que Evoke Pharma Inc est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 3 analystes ont établi des notations d'analystes pour Evoke Pharma Inc, y compris 2 achat fort, 4 achat, 1 maintien, 0 vente et 2 vente forte
